People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Holding Co LLC | — | Pharmaceuticals | Series D+ | $130.0M | $3.9B | 2021 |
| Renasant Bio, Inc. | — | Biotechnology | Series B | $55.5M | $144.0M | 2025 |
Natalie Holles at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Natalie Holles on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Derek DiRocco | 1 | 7 |
| Daniel Becker | 1 | 5 |
| Anna French | 1 | 3 |
| John Josey | 1 | 3 |
| June Lee | 1 | 3 |
| Deborah Palestrant | 1 | 3 |
| Michael Gladstone | 1 | 3 |
| JULIE PAPANEK GRANT | 1 | 2 |
| Evan Caplan | 1 | 2 |
| Emily Conley | 1 | 2 |
| Jeremy Bender | 1 | 1 |
| Charlotte McKee | 1 | 1 |
| Thomas Gustafson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.